AC Immune S.A. (ACIU) Stock

AC Immune S.A. (ACIU) is a Healthcare stock trading at $2.49 (as of 2026-06-22), with a market capitalization of $243.16M and a trailing P/E of -3.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

AC Immune S.A. is a clinical-stage biopharmaceutical company that discovers, designs, and develops medicines and diagnostic products for preventing and treating neurodegenerative diseases linked to protein misfolding. Using its SupraAntigen and Morphomer platforms, it develops vaccines, antibodies, small molecules, and a Tau PET imaging tracer, including clinical-stage programs in Alzheimer’s disease.

Valuation — source: SEC EDGAR (first-party)
Price	$2.49
Market Cap	$243.16M
P/E Ratio	-3.3
Price / Book	5.24
Price / Sales	65.78
DCF Value (model)	$-11.33
DCF Upside vs Price	-555.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$3.57M
Net Margin	-1971.6%
Return on Equity	-157.0%
Current Ratio	1.02
Revenue Growth (YoY)	-86.9%
EPS Growth (YoY)	37.3%

Valuation vs Sector & Industry
Stock P/E	-3.3
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-115.8%
vs Industry	-119.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BVF INC/IL ($54.51M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Andrea Pfeifer
Employees	133
Country	CH
IPO Date	2016-09-23

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-22.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.